Using magnetophoresis and light therapy to treat triple negative breast cancer
Combined magnetophoresis and photodynamic therapy for the treatment of TNBC
This study is exploring a new way to treat triple negative breast cancer by using special techniques that help deliver targeted treatments directly to the cancer cells, which could make surgery and radiation more effective and reduce side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10808207 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating triple negative breast cancer (TNBC) by combining magnetophoresis and photodynamic therapy (PDT). The goal is to enhance the effectiveness of breast-conserving surgery and radiation therapy by using targeted photosensitizers that specifically attack cancer cells. By developing new nanoparticle formulations, the research aims to improve the delivery and efficacy of these treatments while minimizing side effects. Patients may benefit from improved local control of their cancer and potentially better overall survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are considering breast-conserving surgery.
Not a fit: Patients with non-breast cancers or those whose TNBC has progressed to an advanced stage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with triple negative breast cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results using photodynamic therapy in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Tsourkas, Andrew — University of Pennsylvania
- Study coordinator: Tsourkas, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.